Skip to main content
. 2021 Sep 14;12:502. doi: 10.1186/s13287-021-02453-z

Fig. 3.

Fig. 3

In vitro immunomodulatory properties of RA patient-derived SF-MSCs. a Evaluation of inhibited PBMC proliferation. The ratios 1:4, 1:2, and 1:1 indicate the cell population of pre-seeded SF-MSCs and PBMCs. PBMC and PBMC+PHAL indicate PBMC cultures without or with PHAL, respectively. b Comparison of inhibited PBMC proliferation in the highest PBMC to MSC ratio (1:1). c Quantification of IDO secretion after treatment with inflammatory cytokines by ELISA. Con or T indicate cells that were untreated or treated with inflammatory cytokines, respectively. d Evaluation of IDO activity after treatment with IFN-γ by measurement of L-kynurenine. The asterisks indicate significant differences. The data represent mean values ± SD. PBMC, peripheral blood mononuclear cells; PHAL, phytohemagglutinin-L; IDO, indoleamine 2,3-dioxygenase; IFN-γ, interferon-γ